NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/06/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization1,065.93 mln
Float69.28 mln
Earnings Date05/20/2026
Piotroski F-Score
2
/ 9
Weak
Relative Strength
90
/ 100
Top performer
Debt / Equity
-1.97
Negative equity
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Payout Ratio
0.00%
No payout
Business Description
Omeros Corporation is a Seattle-based drug development company founded in 1994 that focuses on treatments for rare immune system diseases. Its most advanced drug candidate, Narsoplimab, targets a serious complication of stem cell transplants and has also been studied as a potential treatment for COVID-19. The company has several other medicines in various stages of testing, addressing conditions ranging from addiction and movement disorders to blood cancers and drug-resistant infections.
